Skip to main content
Top
Published in: Cancer Cell International 1/2015

Open Access 01-12-2015 | Primary research

Multidrug resistance characterization in multicellular tumour spheroids from two human lung cancer cell lines

Authors: Raúl Barrera-Rodríguez, Jorge Morales Fuentes

Published in: Cancer Cell International | Issue 1/2015

Login to get access

Abstract

Background

Most of the knowledge about the mechanisms of multidrug resistance in lung cancer has been achieved through the use of cell lines isolated from tumours cultivated either in suspensions of isolated cells or in monolayers and following exposition to different cytostatic agents. However, tumour cell lines growing as multicellular tumour spheroids (MTS) frequently develop multicellular resistance in a drug-independent form. The aim of this study was to characterize the phenotypic and functional differences between two human NSCLC cell lines (INER-37 and INER-51) grown as traditional monolayer cultures versus as MTS.

Methods

After 72 hours treatment with anticancer drugs, chemosensitivity in monolayers and tumour spheroids cultures was assessed using MTT assay. Reverse transcription-polymerase chain reaction was employed to detect the mRNAs of multidrug resistance-related genes. The expression of P-gp was analyzed by immunohistochemical staining and cell cycle profiles were analyzed using FACS.

Results

The results indicate that when grown as MTS each lung cancer cell line had different morphologies as well as and abrogation of cell proliferation with decrease of the G2/M phase. Also, MTS acquired multicellular resistance to several chemotherapeutic agents in only a few days of culture which were accomplished by significant changes in the expression of MDR-related genes.

Conclusion

Overall, the MTS culture changed the cellular response to drugs nevertheless each of the cell lines studied seems to implement different mechanisms to acquire multicellular resistance.
Literature
1.
go back to reference Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. http://​globocan.​iarc.​fr.
2.
go back to reference Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Eastern cooperative oncology group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–8.PubMedCrossRef Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Eastern cooperative oncology group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–8.PubMedCrossRef
3.
go back to reference Johnson DH, Schiller JH. Recent clinical advances in lung cancer management. J Clin Oncol. 2014;32:973–82.PubMedCrossRef Johnson DH, Schiller JH. Recent clinical advances in lung cancer management. J Clin Oncol. 2014;32:973–82.PubMedCrossRef
4.
go back to reference Lee JK, Hahn S, Kim DW, Suh KJ, Keam B, Kim TM, et al. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. JAMA. 2014;311:1430–7.PubMedCrossRef Lee JK, Hahn S, Kim DW, Suh KJ, Keam B, Kim TM, et al. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. JAMA. 2014;311:1430–7.PubMedCrossRef
5.
go back to reference NSCLC Meta-analyses Collaborative Group, Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375:1267–77.PubMedCentralCrossRef NSCLC Meta-analyses Collaborative Group, Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375:1267–77.PubMedCentralCrossRef
6.
go back to reference Breen L, Keenan J, Clynes M. Generation of lung cancer cell line variants by drug selection or cloning. Methods Mol Biol. 2011;731:125–33.PubMedCrossRef Breen L, Keenan J, Clynes M. Generation of lung cancer cell line variants by drug selection or cloning. Methods Mol Biol. 2011;731:125–33.PubMedCrossRef
7.
go back to reference Sutherland RM. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science. 1988;240:177–84.PubMedCrossRef Sutherland RM. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science. 1988;240:177–84.PubMedCrossRef
8.
go back to reference Olive PL, Durand RE. Drug and radiation resistance in spheroids: cell contact and kinetics. Cancer Metastasis Rev. 1994;13:121–38.PubMedCrossRef Olive PL, Durand RE. Drug and radiation resistance in spheroids: cell contact and kinetics. Cancer Metastasis Rev. 1994;13:121–38.PubMedCrossRef
9.
go back to reference Desoize B, Jardillier J. Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol Hematol. 2000;36:193–207.PubMedCrossRef Desoize B, Jardillier J. Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol Hematol. 2000;36:193–207.PubMedCrossRef
10.
go back to reference Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA. Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol. 2010;148:3–15.PubMedCrossRef Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA. Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol. 2010;148:3–15.PubMedCrossRef
11.
go back to reference Ekert JE, Johnson K, Strake B, Pardinas J, Jarantow S, Perkinson R, et al. Three-dimensional lung tumor microenvironment modulates therapeutic compound responsiveness in vitro–implication for drug development. PLoS One. 2014;9, e92248.PubMedCentralPubMedCrossRef Ekert JE, Johnson K, Strake B, Pardinas J, Jarantow S, Perkinson R, et al. Three-dimensional lung tumor microenvironment modulates therapeutic compound responsiveness in vitro–implication for drug development. PLoS One. 2014;9, e92248.PubMedCentralPubMedCrossRef
12.
go back to reference Durand RE. Slow penetration of anthracyclines into spheroids and tumors: a therapeutic advantage? Cancer Chemother Pharmacol. 1990;26:198–204.PubMedCrossRef Durand RE. Slow penetration of anthracyclines into spheroids and tumors: a therapeutic advantage? Cancer Chemother Pharmacol. 1990;26:198–204.PubMedCrossRef
13.
go back to reference Kumar HR, Zhong X, Hoelz DJ, Rescorla FJ, Hickey RJ, Malkas LH, et al. Three-dimensional neuroblastoma cell culture: proteomic analysis between monolayer and multicellular tumor spheroids. Pediatr Surg Int. 2008;24:1229–34.PubMedCentralPubMedCrossRef Kumar HR, Zhong X, Hoelz DJ, Rescorla FJ, Hickey RJ, Malkas LH, et al. Three-dimensional neuroblastoma cell culture: proteomic analysis between monolayer and multicellular tumor spheroids. Pediatr Surg Int. 2008;24:1229–34.PubMedCentralPubMedCrossRef
14.
go back to reference Wartenberg M, Fischer K, Hescheler J, Sauer H. Modulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by cell cycle inhibitors. Biochim Biophys Acta. 2002;1589:49–62.PubMedCrossRef Wartenberg M, Fischer K, Hescheler J, Sauer H. Modulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by cell cycle inhibitors. Biochim Biophys Acta. 2002;1589:49–62.PubMedCrossRef
15.
go back to reference Wartenberg M, Frey C, Diedershagen H, Ritgen J, Hescheler J, Sauer H. Development of an intrinsic P-glycoprotein-mediated doxorubicin resistance in quiescent cell layers of large, multicellular prostate tumor spheroids. Int J Cancer. 1998;75:855–63.PubMedCrossRef Wartenberg M, Frey C, Diedershagen H, Ritgen J, Hescheler J, Sauer H. Development of an intrinsic P-glycoprotein-mediated doxorubicin resistance in quiescent cell layers of large, multicellular prostate tumor spheroids. Int J Cancer. 1998;75:855–63.PubMedCrossRef
16.
17.
go back to reference Hickman JA, Graeser R, de Hoogt R, Vidic S, Brito C, Gutekunst M, et al. IMI PREDECT Consortium: Three-dimensional models of cancer for pharmacology and cancer cell biology: capturing tumor complexity in vitro/ex vivo. Biotechnol J. 2014;9:1115–28.PubMedCrossRef Hickman JA, Graeser R, de Hoogt R, Vidic S, Brito C, Gutekunst M, et al. IMI PREDECT Consortium: Three-dimensional models of cancer for pharmacology and cancer cell biology: capturing tumor complexity in vitro/ex vivo. Biotechnol J. 2014;9:1115–28.PubMedCrossRef
18.
go back to reference Grantab R, Sivananthan S, Tannock IF. The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res. 2006;66:1033–9.PubMedCrossRef Grantab R, Sivananthan S, Tannock IF. The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res. 2006;66:1033–9.PubMedCrossRef
19.
go back to reference Kwok TT, Twentyman PR. The relationship between tumour geometry and the response of tumour cells to cytotoxic drugs–an in vitro study using EMT6 multicellular spheroids. Int J Cancer. 1985;35:675–82.PubMedCrossRef Kwok TT, Twentyman PR. The relationship between tumour geometry and the response of tumour cells to cytotoxic drugs–an in vitro study using EMT6 multicellular spheroids. Int J Cancer. 1985;35:675–82.PubMedCrossRef
20.
go back to reference Erlanson M, Daniel-Szolgay E, Carlsson J. Relations between the penetration, binding and average concentration of cytostatic drugs in human tumour spheroids. Cancer Chemother Pharmacol. 1992;29:343–53.PubMedCrossRef Erlanson M, Daniel-Szolgay E, Carlsson J. Relations between the penetration, binding and average concentration of cytostatic drugs in human tumour spheroids. Cancer Chemother Pharmacol. 1992;29:343–53.PubMedCrossRef
21.
go back to reference Carlsson J, Acker H. Relations between pH, oxygen partial pressure and growth in cultured cell spheroids. Int J Cancer. 1988;42:715–20.PubMedCrossRef Carlsson J, Acker H. Relations between pH, oxygen partial pressure and growth in cultured cell spheroids. Int J Cancer. 1988;42:715–20.PubMedCrossRef
22.
go back to reference Mueller-Klieser W, Freyer JP, Sutherland RM. Influence of glucose and oxygen supply conditions on the oxygenation of multicellular spheroids. Br J Cancer. 1986;53:345–53.PubMedCentralPubMedCrossRef Mueller-Klieser W, Freyer JP, Sutherland RM. Influence of glucose and oxygen supply conditions on the oxygenation of multicellular spheroids. Br J Cancer. 1986;53:345–53.PubMedCentralPubMedCrossRef
23.
go back to reference Freyer JP. Role of necrosis in regulating the growth saturation of multicellular spheroids. Cancer Res. 1988;48:2432–9.PubMed Freyer JP. Role of necrosis in regulating the growth saturation of multicellular spheroids. Cancer Res. 1988;48:2432–9.PubMed
24.
go back to reference Olive PL, Banáth JP, Evans HH. Cell killing and DNA damage by etoposide in Chinese hamster V79 monolayers and spheroids: influence of growth kinetics, growth environment and DNA packaging. Br J Cancer. 1993;67:522–30.PubMedCentralPubMedCrossRef Olive PL, Banáth JP, Evans HH. Cell killing and DNA damage by etoposide in Chinese hamster V79 monolayers and spheroids: influence of growth kinetics, growth environment and DNA packaging. Br J Cancer. 1993;67:522–30.PubMedCentralPubMedCrossRef
25.
go back to reference Francia G, Man S, Teicher B, Grasso L, Kerbel RS. Gene expression analysis of tumor spheroids reveals a role for suppressed DNA mismatch repair in multicellular resistance to alkylating agents. Mol Cell Biol. 2004;24:6837–49.PubMedCentralPubMedCrossRef Francia G, Man S, Teicher B, Grasso L, Kerbel RS. Gene expression analysis of tumor spheroids reveals a role for suppressed DNA mismatch repair in multicellular resistance to alkylating agents. Mol Cell Biol. 2004;24:6837–49.PubMedCentralPubMedCrossRef
26.
27.
go back to reference Simons SM, Schindler M. Cell biology mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci U S A. 1994;91:3497–504.CrossRef Simons SM, Schindler M. Cell biology mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci U S A. 1994;91:3497–504.CrossRef
28.
go back to reference Mattern J. Drug Resistance in cancer: a multifactorial problem. Anticancer Res. 2003;23:1769–72.PubMed Mattern J. Drug Resistance in cancer: a multifactorial problem. Anticancer Res. 2003;23:1769–72.PubMed
29.
go back to reference Dangles V, Lazar V, Validire P, Richon S, Wertheimer M, Laville V, et al. Gene expression profiles of bladder cancers: evidence for a striking effect of in vitro cell models on gene patterns. Br J Cancer. 2002;86:1283–9.PubMedCentralPubMedCrossRef Dangles V, Lazar V, Validire P, Richon S, Wertheimer M, Laville V, et al. Gene expression profiles of bladder cancers: evidence for a striking effect of in vitro cell models on gene patterns. Br J Cancer. 2002;86:1283–9.PubMedCentralPubMedCrossRef
30.
go back to reference Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer. 2004;4:118–32.PubMedCrossRef Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer. 2004;4:118–32.PubMedCrossRef
31.
go back to reference Garrido C, Chauffert B, Pinard D, Tibaut F, Genne P, Assem M, et al. Circumvention of confluence-dependent resistance in a human multi-drug-resistant colon-cancer cell line. Int J Cancer. 1995;61:873–9.PubMedCrossRef Garrido C, Chauffert B, Pinard D, Tibaut F, Genne P, Assem M, et al. Circumvention of confluence-dependent resistance in a human multi-drug-resistant colon-cancer cell line. Int J Cancer. 1995;61:873–9.PubMedCrossRef
32.
go back to reference Wartenberg M, Ling FC, Müschen M, Klein F, Acker H, Gassmann M, et al. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J. 2003;17:503–5.PubMed Wartenberg M, Ling FC, Müschen M, Klein F, Acker H, Gassmann M, et al. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J. 2003;17:503–5.PubMed
33.
go back to reference Tomida A, Yun J, Tsuruo T. Glucose-regulated stresses induce resistance to camptothecin in human cancer cells. Int J Cancer. 1996;68:391–6.PubMedCrossRef Tomida A, Yun J, Tsuruo T. Glucose-regulated stresses induce resistance to camptothecin in human cancer cells. Int J Cancer. 1996;68:391–6.PubMedCrossRef
34.
go back to reference Kolchinsky A, Roninson IB. Drug resistance conferred by MDR1 expression in spheroids formed by glioblastoma cell lines. Anticancer Res. 1997;17:3321–7.PubMed Kolchinsky A, Roninson IB. Drug resistance conferred by MDR1 expression in spheroids formed by glioblastoma cell lines. Anticancer Res. 1997;17:3321–7.PubMed
35.
go back to reference Ponce de León V, Barrera RR. Changes in P-glycoprotein activity are mediated by the growth of a tumour cell line as multicellular spheroids. Cancer Cell Int. 2005;5:20.PubMedCrossRef Ponce de León V, Barrera RR. Changes in P-glycoprotein activity are mediated by the growth of a tumour cell line as multicellular spheroids. Cancer Cell Int. 2005;5:20.PubMedCrossRef
36.
go back to reference Olive PL, Durand RE, Banáth JP, Evans HH. Etoposide sensitivity and topoisomerase II activity in Chinese hamster V79 monolayers and small spheroids. Int J Radiat Biol. 1991;60:453–66.PubMedCrossRef Olive PL, Durand RE, Banáth JP, Evans HH. Etoposide sensitivity and topoisomerase II activity in Chinese hamster V79 monolayers and small spheroids. Int J Radiat Biol. 1991;60:453–66.PubMedCrossRef
37.
go back to reference de Lucio VM B, Barrera RR. Characterization of human NSCLC cell line with innate etoposide-resistance mediated by cytoplasmic localization of topoisomerase II alpha. Cancer Sci. 2005;96:774–83.CrossRef de Lucio VM B, Barrera RR. Characterization of human NSCLC cell line with innate etoposide-resistance mediated by cytoplasmic localization of topoisomerase II alpha. Cancer Sci. 2005;96:774–83.CrossRef
38.
go back to reference Oloumi A, MacPhail SH, Johnston PJ, Banáth JP, Olive PL. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors. Cancer Res. 2000;60:5747–53.PubMed Oloumi A, MacPhail SH, Johnston PJ, Banáth JP, Olive PL. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors. Cancer Res. 2000;60:5747–53.PubMed
39.
go back to reference Chikamori K, Grozav AG, Kozuki T, Grabowski D, Ganapathi R, Ganapathi MK. DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy. Curr Cancer Drug Targets. 2010;10:758–71.PubMedCrossRef Chikamori K, Grozav AG, Kozuki T, Grabowski D, Ganapathi R, Ganapathi MK. DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy. Curr Cancer Drug Targets. 2010;10:758–71.PubMedCrossRef
40.
go back to reference Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST, Mirabelli CK. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry. 1989;28:8154–60.PubMedCrossRef Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST, Mirabelli CK. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry. 1989;28:8154–60.PubMedCrossRef
41.
go back to reference Cole SP. Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future. Annu Rev Pharmacol Toxicol. 2014;54:95–117.PubMedCrossRef Cole SP. Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future. Annu Rev Pharmacol Toxicol. 2014;54:95–117.PubMedCrossRef
42.
go back to reference Cole SP, Deeley RG. Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacol Sci. 2006;27:438–46.PubMedCrossRef Cole SP, Deeley RG. Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacol Sci. 2006;27:438–46.PubMedCrossRef
43.
go back to reference Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000;92:1295–302.PubMedCrossRef Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000;92:1295–302.PubMedCrossRef
44.
go back to reference Takagi A, Watanabe M, Ishii Y, Morita J, Hirokawa Y, Matsuzaki T, et al. Three-dimensional cellular spheroid formation provides human prostate tumor cells with tissue-like features. Anticancer Res. 2007;27:45–53.PubMed Takagi A, Watanabe M, Ishii Y, Morita J, Hirokawa Y, Matsuzaki T, et al. Three-dimensional cellular spheroid formation provides human prostate tumor cells with tissue-like features. Anticancer Res. 2007;27:45–53.PubMed
Metadata
Title
Multidrug resistance characterization in multicellular tumour spheroids from two human lung cancer cell lines
Authors
Raúl Barrera-Rodríguez
Jorge Morales Fuentes
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2015
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-015-0200-6

Other articles of this Issue 1/2015

Cancer Cell International 1/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine